If you’ve been in biotech long enough, you know NaV1.7 is the target that launched a thousand failures. The sodium channel that, when knocked out genetically, renders people unable to feel pain — making it the most seductive pain target imaginable. And yet, nobody has cracked it systemically. The selectivity challenge has eaten company after company alive.
So here comes Pelthos Therapeutics with a different idea: don’t go systemic. Go topical. Go… ocular. Their subsidiary Channel Therapeutics just dosed the first patient in a Phase 1b/2a trial of CT2000, a NaV1.7 sodium channel inhibitor for eye pain — both acute ocular pain and the chronic ocular surface pain that haunts millions of dry eye disease patients.
It’s a clever reframing of a historically difficult target. By going topical to the eye, you sidestep most of the selectivity and systemic exposure issues that sank earlier NaV1.7 programs. You’re delivering the drug directly to the sensory neurons that are firing pain signals in the cornea and ocular surface. The pharmacology doesn’t need to work everywhere — it just needs to work there.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
The trial is running out of Australia through Channel Therapeutics’ operations there — a common first-in-human strategy for speed and regulatory efficiency. This is the first time CT2000 has been in a human, so we’re at the very beginning of the safety and tolerability story.
What’s interesting is the parent company’s financial position. Pelthos secured a $50 million venture loan facility from Horizon Technology Finance Corporation back in January, with $30 million funded at close and another $20 million available on milestones. That’s real runway. Pelthos is already commercial in dermatology — they sell nitric oxide-based topical therapies — so CT2000 in ophthalmology represents a pipeline expansion into a new therapeutic area, not a bet-the-company moment.
The non-opioid angle matters too. Ocular pain is currently managed with NSAIDs, steroids, and sometimes off-label opioids — none of which are great long-term solutions for chronic dry eye pain. A targeted, non-addictive approach that directly blocks pain signaling at the source would be genuinely differentiated. Early days, but NaV1.7 might finally have found the right address.
